- •
Chemotherapy remains an effective treatment option for BPDCN in fit patients who may be eligible for hematopoietic stem cell transplantation.
- •
The intensity of induction regimens is positively correlated with outcomes in retrospective series but is difficult to disentangle from possible confounders.
- •
Some series suggest “ALL-type” or lymphoid-directed regimens are associated with better outcomes compared with “AML-type” or myeloid-directed regimens.
- •
Low-intensity chemotherapy regimens are of utility
Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm
Section snippets
Key points
Intensive chemotherapy for fit individuals
Given the lack of prospective trials of induction regimens for BPDCN, the best recommendation for treatments used for induction are based on retrospective analyses of patients treated in routine clinical practice. In our experience, whether the patient was referred to a certain subspecialist influenced the treatment decision.4 For example, if referred to a lymphoma specialist the patients tended to get lymphoma regimens, for example, CHOP; however, if referred to a leukemia specialist the
Non-fit individuals
For patients with BDCN who cannot tolerate aggressive therapy, there is limited data for lower-intensity chemotherapy options. As discussed above, Reimer and colleagues5 found that those receiving therapies considered less intensive than CHOP had very poor outcomes (median overall survival = 9 months) with only 7% reporting sustained remissions and no patients with long-term survival. The median age in this group was 79 suggesting that they were likely not eligible for hematopoietic stem cell
Summary
Although BPDCN often presents with skin findings initially, it can be mistaken for non-neoplastic causes resulting in delayed diagnosis. Unless the correct pathologic workup is performed it could also be misdiagnosed for other neoplastic entities resulting in incorrect or delayed treatment. This highlights the need for increased awareness of the disease and the importance of having reliable immunohistochemical and flow cytometry markers, discussed elsewhere in this review series. If BPDCN is
Disclosure
The authors have nothing to disclose.
References (90)
- et al.
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
Blood
(2009) - et al.
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
Blood
(2019) - et al.
Clinicopathological features and prognostic significance of CXCL12 in blastic plasmacytoid dendritic cell neoplasm
J Am Acad Dermatol
(2012) - et al.
Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group
Leuk Res
(2010) - et al.
Clinical and biologic features of CD4(+)CD56(+) malignancies
Blood
(2002) - et al.
Allogeneic hematopoietic cell transplantation is an effective treatment for blastic plasmacytoid dendritic cell neoplasm in first complete remission: systematic review and meta-analysis
Clin Lymphoma Myeloma Leuk
(2018) - et al.
Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm
Blood
(2015) - et al.
CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate
J Am Acad Dermatol
(2008) - et al.
Primary cutaneous blastic plasmacytoid dendritic cell neoplasm without extracutaneous manifestation: case report and review of the literature
Pathol Res Pract
(2011) - et al.
Blastic plasmacytoid dendritic cell neoplasm with acute myeloid leukemia successfully treated to a remission currently of 26 months duration
Leuk Res
(2011)